Last reviewed · How we verify
ADS-5102
ADS-5102 is an extended-release formulation of amantadine that provides sustained dopaminergic and anti-glutamatergic activity to reduce involuntary movements.
ADS-5102 is an extended-release formulation of amantadine that provides sustained dopaminergic and anti-glutamatergic activity to reduce involuntary movements. Used for Levodopa-induced dyskinesia in Parkinson's disease patients.
At a glance
| Generic name | ADS-5102 |
|---|---|
| Also known as | amantadine HCl extended release |
| Sponsor | Adamas Pharmaceuticals, Inc. |
| Drug class | NMDA receptor antagonist / dopamine agonist |
| Target | NMDA receptor, dopamine pathways |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
ADS-5102 delivers amantadine in an extended-release formulation designed to maintain therapeutic levels throughout the day. Amantadine works through multiple mechanisms including NMDA receptor antagonism and dopamine agonism, which help reduce dyskinesia and other movement disorders by modulating glutamatergic and dopaminergic neurotransmission in the basal ganglia.
Approved indications
- Levodopa-induced dyskinesia in Parkinson's disease patients
Common side effects
- Hallucinations
- Dizziness
- Dry mouth
- Constipation
- Peripheral edema
Key clinical trials
- A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment (PHASE3)
- Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment (PHASE3)
- Open-Label Safety Study of ADS-5102 in PD Patients With LID (PHASE3)
- ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study) (PHASE3)
- Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia (PHASE3)
- Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study) (PHASE2, PHASE3)
- Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ADS-5102 CI brief — competitive landscape report
- ADS-5102 updates RSS · CI watch RSS
- Adamas Pharmaceuticals, Inc. portfolio CI